The clinical-stage biotechnology company, founded in 2015 and headquartered in Grand Cayman, is committed to discovering and developing new tools for the patient's immune system to fight various solid tumor malignancies, including renal cell carcinoma, soft tissue sarcoma, and gastric cancer, among others. They use a logic-gated CAR-T platform to harness the power of the immune system to target challenging solid tumor malignancies, allowing patients to access cellular therapies in the future. EXUMA Biotech has rapidly built its core technologies and a growing global presence with operations in China (Shanghai and Shenzhen) and headquarters in West Palm Beach, FL.